DK3099713T3 - Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne - Google Patents
Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne Download PDFInfo
- Publication number
- DK3099713T3 DK3099713T3 DK15701985.2T DK15701985T DK3099713T3 DK 3099713 T3 DK3099713 T3 DK 3099713T3 DK 15701985 T DK15701985 T DK 15701985T DK 3099713 T3 DK3099713 T3 DK 3099713T3
- Authority
- DK
- Denmark
- Prior art keywords
- antagonist domain
- protein consisting
- tnfa
- chemical protein
- ngf
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 title 1
- 102100040247 Tumor necrosis factor Human genes 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934828P | 2014-02-02 | 2014-02-02 | |
| PCT/EP2015/052098 WO2015114150A1 (en) | 2014-02-02 | 2015-02-02 | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3099713T3 true DK3099713T3 (da) | 2020-04-14 |
Family
ID=52440681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15701985.2T DK3099713T3 (da) | 2014-02-02 | 2015-02-02 | Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9884911B2 (enExample) |
| EP (2) | EP3099713B1 (enExample) |
| JP (4) | JP6687526B2 (enExample) |
| KR (1) | KR102489452B1 (enExample) |
| CN (2) | CN106459190A (enExample) |
| AU (3) | AU2015212787B2 (enExample) |
| CA (1) | CA2938066C (enExample) |
| CY (1) | CY1123248T1 (enExample) |
| DK (1) | DK3099713T3 (enExample) |
| ES (1) | ES2784238T3 (enExample) |
| HR (1) | HRP20200477T1 (enExample) |
| HU (1) | HUE048478T2 (enExample) |
| LT (1) | LT3099713T (enExample) |
| MX (1) | MX382763B (enExample) |
| PL (1) | PL3099713T3 (enExample) |
| PT (1) | PT3099713T (enExample) |
| RS (1) | RS60156B1 (enExample) |
| RU (1) | RU2678810C2 (enExample) |
| SI (1) | SI3099713T1 (enExample) |
| SM (1) | SMT202000182T1 (enExample) |
| WO (1) | WO2015114150A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3099713B1 (en) * | 2014-02-02 | 2020-01-15 | MedImmune Limited | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| AU2018337686B2 (en) | 2017-09-21 | 2023-04-20 | Merck Patent Gmbh | Fusion protein comprising an FGF-18 moiety |
| WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
| AU2021350424A1 (en) | 2020-09-28 | 2023-06-01 | Medimmune Limited | Compounds and methods for treating pain |
| CN114574444B (zh) * | 2020-12-01 | 2024-05-03 | 达达生物技术(北京)有限公司 | 自体纤维母细胞在制备抗类风湿关节炎药物中的应用 |
| TWI821881B (zh) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | 腫瘤壞死因子α重組抗體及其用途 |
| CN116179667A (zh) * | 2022-09-21 | 2023-05-30 | 福建中妆技术研究有限公司 | 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DK0939121T4 (da) | 1989-09-12 | 2008-02-04 | Ahp Mfg B V | TNF-bindende proteiner |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1042459A4 (en) * | 1997-12-24 | 2003-07-23 | Diatech Pty Ltd | BIFUNCTIONAL MOLECULES |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| DE19926068C1 (de) * | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| AU2002308722B2 (en) | 2001-05-30 | 2007-05-17 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| CN101107268B (zh) | 2005-01-24 | 2012-06-27 | 剑桥抗体技术有限公司 | 针对ngf的特异性结合成员 |
| NZ596865A (en) * | 2006-06-12 | 2013-07-26 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| KR20100021601A (ko) * | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| EP2275431A3 (en) | 2008-01-18 | 2011-05-25 | Bio-Rad Laboratories, Inc. | Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography |
| AU2009256250B2 (en) | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| SG192489A1 (en) * | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| JP2011016676A (ja) * | 2009-07-07 | 2011-01-27 | Sumitomo Electric Ind Ltd | 窒化物半導体基板の製造方法 |
| PH12012500691A1 (en) * | 2009-10-15 | 2012-11-12 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ， インコーポレイテッド | Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法 |
| EP2555797A4 (en) * | 2010-04-07 | 2014-02-12 | Abbvie Inc | TNF-ALPHA-BINDING PROTEINS |
| WO2012162561A2 (en) * | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CN103906533A (zh) | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| AR090047A1 (es) | 2011-12-30 | 2014-10-15 | Abbvie Inc | Dominio variable dual de inmunoglobulinas y sus usos |
| WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| BR112015023557A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligações dual específicas direcionadas contra tnfa |
| EP3099713B1 (en) | 2014-02-02 | 2020-01-15 | MedImmune Limited | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20210009671A1 (en) | 2019-05-10 | 2021-01-14 | Medimmune Limited | Compounds and methods for treating pain |
-
2015
- 2015-02-02 EP EP15701985.2A patent/EP3099713B1/en active Active
- 2015-02-02 AU AU2015212787A patent/AU2015212787B2/en active Active
- 2015-02-02 HU HUE15701985A patent/HUE048478T2/hu unknown
- 2015-02-02 JP JP2016549449A patent/JP6687526B2/ja active Active
- 2015-02-02 US US14/612,137 patent/US9884911B2/en active Active
- 2015-02-02 HR HRP20200477TT patent/HRP20200477T1/hr unknown
- 2015-02-02 RU RU2016132370A patent/RU2678810C2/ru active
- 2015-02-02 MX MX2016010030A patent/MX382763B/es unknown
- 2015-02-02 ES ES15701985T patent/ES2784238T3/es active Active
- 2015-02-02 PL PL15701985T patent/PL3099713T3/pl unknown
- 2015-02-02 PT PT157019852T patent/PT3099713T/pt unknown
- 2015-02-02 WO PCT/EP2015/052098 patent/WO2015114150A1/en not_active Ceased
- 2015-02-02 KR KR1020167023831A patent/KR102489452B1/ko active Active
- 2015-02-02 CN CN201580017113.5A patent/CN106459190A/zh active Pending
- 2015-02-02 DK DK15701985.2T patent/DK3099713T3/da active
- 2015-02-02 EP EP19214210.7A patent/EP3696193A1/en active Pending
- 2015-02-02 RS RS20200396A patent/RS60156B1/sr unknown
- 2015-02-02 CA CA2938066A patent/CA2938066C/en active Active
- 2015-02-02 CN CN202311359790.8A patent/CN118085103A/zh active Pending
- 2015-02-02 SI SI201531149T patent/SI3099713T1/sl unknown
- 2015-02-02 SM SM20200182T patent/SMT202000182T1/it unknown
- 2015-02-02 LT LTEP15701985.2T patent/LT3099713T/lt unknown
-
2017
- 2017-12-21 US US15/849,771 patent/US10457728B2/en active Active
-
2019
- 2019-09-17 US US16/573,192 patent/US11053307B2/en active Active
-
2020
- 2020-04-01 JP JP2020065513A patent/JP7074792B2/ja active Active
- 2020-04-10 CY CY20201100338T patent/CY1123248T1/el unknown
- 2020-09-11 AU AU2020230316A patent/AU2020230316B2/en active Active
-
2021
- 2021-05-28 US US17/333,291 patent/US11897949B2/en active Active
-
2022
- 2022-05-11 JP JP2022077858A patent/JP7520070B2/ja active Active
-
2023
- 2023-12-21 AU AU2023285832A patent/AU2023285832A1/en active Pending
-
2024
- 2024-01-03 US US18/403,043 patent/US20240262902A1/en not_active Abandoned
- 2024-07-08 JP JP2024109298A patent/JP2024133644A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282048A (en) | Oxysterols and methods of use thereof | |
| DK3164489T3 (da) | Mærkning og vurdering af en målsekvens | |
| DK3099713T3 (da) | Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne | |
| DK3183774T3 (da) | Indretning og fremgangsmåde til ledning af elektromagnetiske bølger | |
| DK3529257T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK4105223T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3179991T3 (da) | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor | |
| DK3172213T3 (da) | Makrocykliske kinasehæmmere og anvendelser deraf | |
| DK3178258T3 (da) | Justering af målingsmellemrum og opdagelsessignaler | |
| DK3227310T3 (da) | Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer | |
| DK3122359T3 (da) | Kombinationer af en fgfr-inhibitor og en igf1r-hæmmer | |
| DK3156503T3 (da) | Mavecancer-biomarkør og detektionsfremgangsmåde | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3054744T3 (da) | Lederforbindelse og lederforbindelseskomponent | |
| DK3132049T3 (da) | Enhed og fremgangsmåder til anvendelse af enhed til detektering af aminoacidopatier | |
| PT3383991T (pt) | Dispositivo de foto-biorreator e métodos | |
| DK3212659T3 (da) | Midler og fremgangsmåder til stedspecifik funktionalisering af polypeptider | |
| DK3072560T3 (da) | Trampolinsystemer og fremgangsmåder til fremstilling og anvendelse deraf | |
| DK3146320T3 (da) | Detekteringsanordning og fremgangsmåde | |
| PL3152048T3 (pl) | Urządzenie i sposób tłumienia dźwięków elementu konstrukcyjnego |